Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 429

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 429
---
, or we are unable to conclude in our quarterly and annual reports that our disclosure controls and procedures are effective, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of the Company Shares could be negatively affected, and we could become subject to investigations by the stock exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial and management resources. If we fail to remediate any material weakness, our financial statements could be inaccurate, and we could face restricted access to capital markets. See “ Risk Factors — Additional Risks Related to the Business Combination — We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business and the price of our ordinary shares.” 222

Certain Company Relationships and Related Party Transactions The table below sets for the entities the Company has engaged in related party transactions with and their relationships to the Company.

| Related Party                        |     | Relationship to the Company                                                                                                                                                                          |
| Bioceres Group PLC                   |     | A company organized under the laws of England and Wales and an indirect shareholder of the Company.                                                                                                  |
| Centro de Diagnóstico Médico de Alta 
 Complejidad S.A.                     |     | A company organized under the laws of Argentina and an indirect shareholder of the Company.                                                                                                          |
| Theo I SCSp                          |     | A special limited partnership governed by the laws of the Grand Duchy of Luxembourg and subsidiary of Bioceres S.A., an affiliate of Bioceres Group PLC, and an indirect shareholder of the Company. |

Commercial Operations Heritas Argentina conducted commercial operations in the ordinary course of business in arm’s length transactions under market terms with the Company. On November 1, 2023, Heritas Argentina and CIBIC entered into a lease agreement for Argentine Wet -Lab, located in Rosario, pursuant to which certain laboratory installations would be made available to Heritas Argentina from CIBIC, for monthly payments in the amount of $3,650, beginning on November 1, 2023 through October 30, 2026. On February 19, 2024, Heritas Argentina and CIBIC entered into an IT services agreement for monthly payments in the amount of $1,500, pursuant to which CIBIC would provide IT support to